Khan, K.; Kostoula, V.; Savage, K.; Stubbs, M.; McStay, M.; Dhillon, A.P.; Caplin, M.E.
April 2003
Gut;Apr2003 Supplement 1, Vol. 52, pA91
Academic Journal
Introduction: Glivec (imatinib mesylate) is currently being used in clinical trials for the treatment of gastrointestinal stromal tumours and is known to specifically inhibit the tyrosine coupled receptor encoded by the c-kit proto-oncogene. Glivec is currently being assessed as a therapeutic possibility in other c-kit positive tumours. Aim: To assess the expression of c-kit (CD117) in neuroendocrine tumours. Methods: Immunohistochemistry was performed on paraffin embedded sections from 62 consecutive NET patients: 36 carcinoid, 16 pancreatic NET, 5 paraganglioma and 5 medullary carcinoma of thyroid. C-kit (CDl17) polyclonal antibody (Dakocytomation) raised against synthesised c-kit peptide was used followed by a horseradish peroxidase detection step for immunohistochemistry. Appropiate negative controls were carried out simultaneously. Results: 36% of carcinoids and 18% of pancreatic NET demonstrated expression of c-kit (CD117). No staining was observed on paragangliomas and medullary carcinoma of thyroid. Conclusion: Immunohistochemical studies have demonstrated the presence of c-kit (CD117) in carcinoid andpancreatic neuroendocrine tumours, with the most expression observedin carcinoid. With limited treatment availability, Glivec may have therapeutic efficacy in the treatment of selected tumour patients.


Related Articles

  • Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Judson, Ian; Peiming Ma; Bin Peng; Verweij, Jaap; Racine, Amy; Paola, Eugenio; Glabbeke, Martine; Dimitrijevic, Sasa; Scurr, Michelle; Dumez, Herlinde; Oosterom, Allan; Ma, Peiming; Peng, Bin; di Paola, Eugenio Donato; van Glabbeke, Martine; van Oosterom, Allan // Cancer Chemotherapy & Pharmacology;Apr2005, Vol. 55 Issue 4, p379 

    Imatinib pharmacokinetics (PK) may be affected by a number of factors that are related to the disease being treated and to the response of that disease to imatinib. Patients in the phase I and phase II trials conducted by the EORTC in patients with gastrointestinal stromal tumours (GISTs) and...

  • Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile? Tielen, Ronald; Verhoef, Cornelis; van Coevorden, Frits; Gelderblom, Hans; Sleijfer, Stefan; Hartgrink, Henk H.; Bonenkamp, Johannes J.; van der Graaf, Winette T.; de Wilt, Johannes H. W. // World Journal of Surgical Oncology;2012, Vol. 10 Issue 1, p111 

    Background: Standard treatment for metastatic gastrointestinal stromal tumors (GISTs) is systemic therapy with imatinib. Surgery is performed to remove metastatic lesions to induce long-term remission or even curation. In other patients, surgery is performed to remove (focal) progressive or...

  • Imatinib mesylate acts in metastatic or unresectable gastrointestinal stromal tumor by targeting KIT receptors-a review. Sawaki, Akira; Yamao, Kenji // Cancer Chemotherapy & Pharmacology. Supplement;Sep2004, Vol. 54, pS44 

    Gastrointestinal stromal tumor (GIST) is the most common mesenchymal malignancy of the gastrointestinal tract. This tumor is resistant to conventional chemotherapy and radiotherapy. Although surgery has been the only effective treatment for GIST to date, it is not enough to manage metastatic...

  • Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors. Blay, J.-Y.; Pérol, D.; Le Cesne, A. // Annals of Oncology;Jul2012, Vol. 23 Issue 7, p1659 

    Background Imatinib is the standard of care for patients with advanced gastrointestinal stromal tumors (GIST). Design This article reviews recent data on the impact of imatinib treatment interruption and subsequent rechallenge in patients with advanced GIST. Results The randomized BFR14 trial...

  • S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors. BLANKE, CHARLES D.; RANKIN, CATHY; CORLESS, CHRISTOPHER; EARY, JANET F.; MULDER, KAREN; OKUNO, SCOTT H.; GEORGE, SUZANNE; HEINRICH, MICHAEL // Oncologist;Dec2015, Vol. 20 Issue 12, p1353 

    Background. Imatinib mesylate, a potent inhibitor of the KIT and PDGFR tyrosine kinases, is highly effective in the treatment of advanced gastrointestinal stromal tumors (GISTs). However, most imatinib-treated tumors eventually become resistant, accounting for a median progression-free survival...

  • FEATURE | Oral therapy for GIST.  // Oncology Nurse Advisor;Nov/Dec2012, Vol. 3 Issue 6, p1 

    The article provides information on oral therapy for gastrointestinal stromal tumor (GIST) including incidence of grade 3 effects to imatinib in patients with unresectable/metastatic GIST, advocacy groups for patients with GIST, and Programs that provide financial assistance to patients.

  • Efficacy and Economic Value of Adjuvant Imatinib for Gastrointestinal Stromal Tumors. RUTKOWSKI, PIOTR; GRONCHI, ALESSANDRO // Oncologist;Jun2013, Vol. 18 Issue 6, p689 

    Objective. This article presents the clinical effectiveness and cost-effectiveness of the use of adjuvant imatinib mesylate for treating patients with localized primary gastrointestinal stromal tumors (GISTs) and discusses the impact of prolonged treatment with adjuvant imatinib on health care...

  • Adjuvant Therapy for High-Risk Gastrointestinal Stromal Tumour: Considerations for Optimal Management. Joensuu, Heikki // Drugs;2012, Vol. 72 Issue 15, p1953 

    One randomized trial has found that adjuvant treatment with imatinib for gastrointestinal stromal tumour (GIST) 3 cm or larger in diameter prolongs recurrence-free survival, and another trial has reported that 3 years of adjuvant imatinib improves both recurrence-free and overall survival...

  • Unresectable gastrointestinal stromal tumors. Menon, Prema; Bansal, Deepak; Rao, K. L. N. // Journal of Indian Association of Pediatric Surgeons;Apr-Jun2011, Vol. 16 Issue 2, p78 

    A letter to the editor is presented in response to the article "Gastrointestinal stromal tumors" in the October 2010 issue.


Read the Article


Sign out of this library

Other Topics